Cost analysis of migraine pharmacotherapy with selective 5HT1 receptor agonists in Ukraine

被引:0
|
作者
Hrynkiv, Yaryna [1 ]
Zaliska, Olha [1 ]
Maksymovych, Nataliia [1 ]
Blavatska, Oksana [1 ]
机构
[1] Danylo Halytsky Lviv Natl Med Univ, Lvov, Ukraine
关键词
selective 5HT1-receptor agonists; zolmitriptan; rizatriptan; sumatriptan; frovatriptan; cost of pharmacotherapy; migraine attack; RIZATRIPTAN;
D O I
10.3897/pharmacia.68.e51740
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The cost analysis for the relief of migraine attack using selective 5HT1-receptor agonists (frovatriptan, zolmitriptan, risatriptan, sumatriptan) of domestic and imported manufacturers in various dosages and forms of production in the proposed resource online pharmacy chains of Lviv for their efficient and cost effective applications. Among the registered drugs, most dosage forms and trade names are presented for sumatriptan; slightly less for risatriptan and zolmitriptan; for frovatriptan is only one trade name. It has been found that to relieve migraine attack with domestic drugs will be cheaper for patients than imported. Packaging with the same dosage of active ingredient, but with more tablets in the blister is more cost effective for patients. It`s the most economical to stop the migraine attack with Stopmigren (sumatriptan) at a dosage of 50 mg, packing 6 tablets in a blister, and the most valuable drug is Rapimig (zolmitriptan) at a dosage of 50 mg, packing 6 tablets in a blister.
引用
收藏
页码:235 / 241
页数:7
相关论文
共 50 条
  • [41] Screening for new 5HT1A receptor agonists and antagonists
    Chilmonczyk, Zdzislaw
    Mazurek, Andrzej
    Plucinski, Franciszek
    Mazurek, Aleksander P.
    Bojarski, Andrzej J.
    PHARMACOLOGICAL REPORTS, 2010, 62 : 38 - 38
  • [42] Discovery and development of selective 5-HT2C receptor agonists for obesity
    Dourish, C. T.
    Adams, D. R.
    Bentley, J.
    Benwell, K.
    Bickerdike, M. J.
    Harrison, K.
    Kennett, G. A.
    Knight, A. R.
    Lightowler, S. L.
    Malcolm, C.
    Misra, A.
    Vickers, S. P.
    Cliffe, I. A.
    Coassolo, P.
    Frei, B.
    Mizrahi, J.
    Stalder, H.
    Stephan-Guldner, M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 127 - 127
  • [43] Cognitive effects of psilocybin, the role of 5HT1 and 5HT2 receptors in cognition"
    Vollenweider, Franz X.
    Hell, Daniel
    Robbins, Trevor
    Geyer, Mark A.
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 101 : 22 - 22
  • [44] 5-thienyltryptamine derivatives as serotonin 5-HT1B/1D receptor agonists: Potential treatment for migraine.
    Slassi, AM
    Meng, CQ
    Rakhit, S
    Wang, X
    Lee, DKH
    Dyne, K
    McCallum, KL
    Mazzacco, L
    Kamboj, R
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U58 - U58
  • [45] Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats
    Gregory V. Carr
    Lee E. Schechter
    Irwin Lucki
    Psychopharmacology, 2011, 213 : 499 - 507
  • [46] Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats
    Carr, Gregory V.
    Schechter, Lee E.
    Lucki, Irwin
    PSYCHOPHARMACOLOGY, 2011, 213 (2-3) : 499 - 507
  • [47] Discovery of a new series of 5-HT1A receptor agonists
    Franchini, Silvia
    Prandi, Adolfo
    Sorbi, Claudia
    Tait, Annalisa
    Baraldi, Annamaria
    Angeli, Piero
    Buccioni, Michela
    Cilia, Antonio
    Poggesi, Elena
    Fossa, Paola
    Brasili, Livio
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (06) : 2017 - 2020
  • [48] 5-HT1-LIKE RECEPTOR AGONISTS ENHANCE WAKEFULNESS
    DZOLJIC, MR
    UKPONMWAN, OE
    SAXENA, PR
    NEUROPHARMACOLOGY, 1992, 31 (07) : 623 - 633
  • [49] Screening for new 5HT1A receptor agonists and antagonists
    Zdzisław Chilmończyk
    Andrzej Mazurek
    Franciszek Pluciński
    Aleksander P. Mazurek
    Andrzej J. Bojarski
    Pharmacological Reports, 2010, 62 : 38 - 38
  • [50] PharmacoMRI imaging of 5-HT1A receptor biased agonists
    Zimmer, L.
    Vidal, B.
    Bolbos, R.
    Redoute, J.
    Langlois, J. B.
    Costes, N.
    Newman-Tancredi, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 8 - 8